Tribute Pharmaceuticals receives notice of Allowance for Canadian patent expanding Cambia use in migraine treatment

The issuance of the new patent will expand Tribute's intellectual property protection for Cambia, currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.

This patent, which was developed by APR Applied Pharma Research s.a. (APR), a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada through a sub-license agreement with Depomed. Depomed has the exclusive North American rights to Cambia licensed with APR. The issuance of the new patent will expand Tribute's intellectual property protection for Cambia, currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.

"This important Canadian patent allowance extends our core intellectual property protection in a market that has been strategically significant to us since the initial launch of Cambia in Canada in October 2012," stated Rob Harris, Tribute's President and Chief Executive Officer. "This new patent extends our intellectual property rights to 6 June 2026." IMS Health, an audited third party provider of sales data, reported an 89.2% increase in total prescriptions written for Cambia during the three months ended 30 September 2015 compared to the three months ended 30 September 2014.